BioVie (BIVI) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

BIVI BioVie

Watchlist

2.230
+0.050+2.29%

Close Jan 3 16:00 ET

2.250
+0.020+0.88%

Post 18:54 ET

39.62MMarket Cap-0.44P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BioVie Files to Sell 7.71M Shares of Common Stock for Holders
TipRanksNov 21, 2024 17:35 ET
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
GlobeNewswireNov 20, 2024 08:00 ET
BioVie | 10-Q: Q1 2025 Earnings Report
SECNov 13, 2024 16:52 ET · Announcements
Express News | BioVie Inc - Pd-202 Trial Expected to Start Early 2025, Results by Late 2025
ReutersNov 4, 2024 08:00 ET
BioVie's Upcoming Parkinson's Disease Clinical Trial Is Fully Funded
Yahoo FinanceNov 4, 2024 08:00 ET
Express News | Biovie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
ReutersNov 4, 2024 08:00 ET

Comments

Jaguar8

Nov 20, 2024 07:07

NEWS

$BioVie (BIVI.US)$
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie (NASDAQ: BIVI) announced the acceptance of an abstract detailing their planned Phase 2 trial of bezisterim for Long COVID treatment at the Demystifying Long COVID International Conference in Barcelona. The study, fully funded by the U.S. Department of Defense, will be a double-blind, randomized, placebo-controlled tri...